文献速递肿瘤 PET/CT

高危恶性黑色素瘤患者接受辅助免疫治疗期间FDG-PET/CT随访的诊断准确性及临床影响

The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-02-07

本研究回顾性纳入124例接受辅助免疫治疗的高危恶性黑色素瘤术后患者,评估术后第一年FDG-PET/CT诊断复发的准确性与临床影响。复发率为每人年0.27(95%CI 0.17-0.37),总敏感性97%、特异性82%、阳性预测值39%、阴性预测值99%。作者认为高危患者复发率高,需重视随访,但中等偏低特异性带来的假阳性潜在危害需与早期发现复发的获益权衡。

要点

  • 术后第一年复发率为每人年0.27(95%CI 0.17-0.37),3个月扫描检出13例(10%)。
  • 总敏感性97%、特异性82%、阳性预测值39%、阴性预测值99%。
  • 阳性预测值随疾病分期升高呈升高趋势,3个月扫描阳性后多数处理为手术或提前后续随访扫描。

核心结论

  • 高危恶性黑色素瘤接受辅助免疫治疗患者复发率高,强调随访的必要性。
  • 中等偏低特异性反映大量假阳性结果,其潜在危害需与早期发现复发的获益相权衡。

研究设计与样本

  • 回顾性纳入124例切除术后高危恶性黑色素瘤患者,均接受辅助免疫治疗并随访FDG-PET/CT。
  • 从病历获取临床信息及AJCC-8分期,复发经活检或后续扫描进展并导致治疗改变验证,无复发假定为至后续随访扫描未见转移。

主要发现

  • 术后第一年恶性黑色素瘤复发率为每人年0.27(95%CI 0.17-0.37)。
  • 3个月FDG-PET/CT检出复发13例(10%),6个月10例(8.1%),9个月1例(0.8%),12个月3例(2.4%)。
  • 总敏感性97%(95%CI 86-99),特异性82%(95%CI 78-86),阳性预测值39%(95%CI 29-50),阴性预测值99%(95%CI 98-99)。
  • 阳性预测值随疾病分期升高呈升高趋势。
  • 3个月扫描时,阳性发现所衍生的多数处理为手术或提前后续随访扫描。

关键数值与推荐

  • 总敏感性97%(95%CI 86-99),特异性82%(95%CI 78-86)。
  • 总阳性预测值39%(95%CI 29-50),阴性预测值99%(95%CI 98-99)。
  • 复发率每人年0.27(95%CI 0.17-0.37)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The benefit of FDG-PET/CT in follow-up of patients treated with adjuvant immunotherapy after resection of high-risk malignant melanoma (MM) is debated. This study evaluated the diagnostic accuracy and clinical impact of FDG-PET/CT for diagnosing MM recurrence during the first year after surgery. METHODS: We retrospectively included 124 patients with resected high-risk MM, who received adjuvant immunotherapy and follow-up FDG-PET/CT. Clinical information and AJCC-8 stage was obtained from patients' medical records. Recurrence was verified by biopsy/progression on a subsequent scan leading to change of treatment. Non-recurrence was assumed when no metastases were observed until the subsequent follow-up scan. Incidence of recurrence, sensitivity, specificity, positive and negative predictive values (PPV and NPV) were outcome measures. RESULTS: Incidence rate of MM recurrence was 0.27 [95% CI 0.17-0.37] per person-year during the first-year. Recurrence was detected in 13 patients (10%) at 3-month FDG-PET/CT, in 10 patients (8.1%) at 6 months, 1 patient (0.8%) at 9 months, 3 patients (2.4%) at 12 months. The overall sensitivity, specificity, PPV, and NPV were 97% [86-99], 82% [78-86], 39% [29-50], and 99% [98-99], respectively. The PPV trended towards higher values as disease stage increased. At the 3-month scan, the majority of actions derived from positive findings were surgery or earlier expedition of the subsequent follow-up scan. CONCLUSION: The high rate of recurrence in patients with high-risk MM treated with adjuvant immunotherapy emphasizes the need for follow-up. The potential harm by a moderately low specificity reflecting a high number of false-positive results must be weighed against the benefit of early detection of recurrence.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Andersen JAS, Spatzek AD, Vilstrup MH, et al. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 35129651. doi:10.1007/s00259-022-05704-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。